About bsbh

This author has not yet filled in any details.
So far bsbh has created 203 blog entries.

Don’t Believe the Hype – International Reference Pricing Will Cost Far More than 1% of R&D Budgets

By Duane Schulthess

It’s odd that a city like Brussels managed to carve itself out a niche as one of the major political centres of the world. The medieval site of a notoriously typhus infested bog, one of the main streets in downtown, ‘Rue du Marais’, literally means, “Street of the Swamp” and the name of the city itself comes from the old Flemish word Broekzele, which roughly translates to ‘settlement in the swamp.’ So, when one talks politically of draining the swamp, at least in Brussels, it carries a literal interpretation that is often distant from the current political climate in DC.

Don’t Believe the Hype – International Reference Pricing Will Cost Far More than 1% of R&D Budgets2019-01-09T08:16:52+00:00

Better Science, Better Health: EUCOPE Sits at Ground Zero in the IP and Orphan Drug Debates

Podcast - Better Science, Better Health: EUCOPE Sits at Ground Zero in the IP and Orphan Drug Debates EUCOPE is Europe’s principal trade body for small to medium-sized biotechnology companies working in areas often targeting orphan diseases. In this podcast we're joined by Alexander Natz, EUCOPE’s Secretary General, and Delphine Roulland, Senior Manager Public [...]

Better Science, Better Health: EUCOPE Sits at Ground Zero in the IP and Orphan Drug Debates2018-12-20T15:39:35+00:00

Better Science, Better Health: Amr Makady of ZiN, wrote the book, LITERALLY, on how to use RWE to value new therapies

Amr Makady of ZiN, wrote the book, LITERALLY, on how to use RWE to value new therapies Many HTAs in Europe are seen as conservative and even reactionary when it comes to innovating or changing their processes. However, Amr's PhD thesis is a 300+ page ‘how to’ manual highlighting RWE best practices [...]

Better Science, Better Health: Amr Makady of ZiN, wrote the book, LITERALLY, on how to use RWE to value new therapies2018-11-30T09:28:21+00:00

Better Science, Better Health: BIA’s CEO is the hardest working man in biotech since Brexit

Podcast - Better Science, Better Health: BIA’s CEO is the hardest working man in biotech since Brexit In this podcast, Steve Bates, the UK BioIndustry Association's CEO, discusses both the challenges and opportunities of Brexit on the UK’s biotechnology sector, and the need for strong, vital IP supported by private investment.Steve was an advisor to [...]

Better Science, Better Health: BIA’s CEO is the hardest working man in biotech since Brexit2018-11-19T13:40:26+00:00

Investing in EU Biotech IP – What Works?

4 December 2018 - 2.00-3.00pm CET, 8.00-9.00am ET

In this webinar we:
• Highlight the results of the research
• Expand on the datapackage used
• Discuss the gap between EU and US IP productivity in healthcare
• Address the need for IP in the global biotech sector

Download Video & Slides

Investing in EU Biotech IP – What Works?2018-12-06T15:11:31+00:00

Podcast – Better Science, Better Health: The US Chamber’s Patrick Kilbride on the Rapidly Changing IP World

Podcast - Better Science, Better Health: The US Chamber's Patrick Kilbride on the Rapidly Changing IP World Patrick Kilbride is vice president of international intellectual property for the Global Innovation Policy Center (GIPC) at the U.S. Chamber of Commerce. Over the last several years, there has been a growing chorus of voices [...]

Podcast – Better Science, Better Health: The US Chamber’s Patrick Kilbride on the Rapidly Changing IP World2018-11-19T13:40:36+00:00

Better Science, Better Health – Stirring the IP Pot

Podcast - Better Science, Better Health: Stirring the IP Pot Emil Pot was one of the founders of ActoGeniX, which was successfully acquired in 2015 by Intrexon. Emil outlines the ingredients Europe needs to build a company from scratch, and leverage home-grown Intellectual Property.

Better Science, Better Health – Stirring the IP Pot2018-11-19T13:40:46+00:00

In the press

Press Room From: Morning Health Care Europe <morninghealth@politico.eu> Date: Fri, 5 Oct 2018 at 06:57 Subject: POLITICO Pro Morning Health Care: After Austria comes Romania — Cancer research cash To: POLITICO Europe Subscribers https://www.politico.eu/pro/politico-pro-morning-health-care-after-austria-comes-romania-cancer-research-cash-trans-fats/?utm_source=POLITICO.EU&utm_campaign=0abbd30995-EMAIL_CAMPAIGN_2018_10_04_08_23&utm_medium=email&utm_term=0_10959edeb5-0abbd30995-189777477 RESEARCH — DOES COMMISSION FUNDING MATTER? A study presented Thursday at Gastein made the argument that private funding correlates [...]

In the press2018-10-19T13:10:19+00:00

Podcast – Better Science, Better Health: VIB’s Johan Cardoen, An EU Biotech Success Story

Podcast - Better Science, Better Health: VIB’s Johan Cardoen, An EU Biotech Success Story For the first podcast in our series investigating the impact and importance of IP on European biotech and innovation, we have an in-depth discussion with Johan Cardoen of VIB, Gent’s life sciences research institute in Belgium. VIB has been called by Reuters, “part [...]

Podcast – Better Science, Better Health: VIB’s Johan Cardoen, An EU Biotech Success Story2018-11-19T13:40:55+00:00

Supporting IP in Europe


Vital Transformation leads a new consortia investigating the relationship between public funding and private investment into new innovative therapies and the supporting system of IP.

This project will develop original research investigating the success factors that create successful EU biotech companies and communicate the importance of IP in creating an ecosystem where investors are willing to lose everything 92% of the time, in order to fund the 8% of medical breakthroughs that succeed.

More Info

Supporting IP in Europe2018-11-16T15:09:54+00:00